DataVXACS Applied Materials & InterfacesPaper
journal article·2020-10-07Open access

Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines

Ruoyu Cheng, Flavia Fontana, Junyuan Xiao, Zehua Liu, Patrícia Figueiredo, Mohammad-Ali Shahbazi, Shiqi Wang, Jing Jin, Giulia Torrieri, Jouni T. Hirvonen, Hongbo Zhang, Tongtong Chen, Wenguo Cui, Yong Lu, Hélder A. Santos

ACS Applied Materials & Interfaces· Volume 12· Issue 40
Publisher pageOpen full text
Source abstract

Abstract

Recently, there has been an increasing interest for utilizing the host immune system to fight against cancer. Moreover, cancer vaccines, which can stimulate the host immune system to respond to cancer in the long term, are being investigated as a promising approach to induce tumor-specific immunity. In this work, we prepared an effective cancer vaccine (denoted as "vacosome") by reconstructing the cancer cell membrane, monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg phosphatidylcholine. The vacosome triggered and enhanced bone marrow dendritic cell maturation as well as stimulated the antitumor response against breast cancer 4T1 cells in vitro. Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that, the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, 200025 Shanghai, PR China

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan University of Medical Sciences, 45139-56184 Zanjan, Iran

Department of Pharmaceutical Sciences Laboratory and Turku Center for Biotechnology, Åbo Akademi University, FI-20520 Turku, Finland

Radiology Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, 200025 Shanghai, PR China

Helsinki Insititute of Life Science, HiLIFE, University of Helsinki, FI-00014 Helsinki, Finland

Funding

Sigrid Jus?liuksen S??ti? · Terveyden Tutkimuksen Toimikunta · Shanghai Municipal Education Commission · Jenny ja Antti Wihurin Rahasto · China Scholarship Council · National Natural Science Foundation of China · H2020 European Research Council · Suomen Kulttuurirahasto · Project of the Action Plan of Major Diseases Prevention and Treatment · HiLIFE Research Funds · Shanghai talent development fund

References (42)

Show source-provided references
1. 10.1038/nature2299110.1038/nature22991 ↗
2. 10.1038/nmat482210.1038/nmat4822 ↗
3. 10.1038/nature1895210.1038/nature18952 ↗
4. 10.1038/s41467-019-13744-810.1038/s41467-019-13744-8 ↗
5. 10.1126/scitranslmed.aao593110.1126/scitranslmed.aao5931 ↗
6. 10.1038/s41467-018-03915-410.1038/s41467-018-03915-4 ↗
7. 10.1016/j.jconrel.2018.10.00810.1016/j.jconrel.2018.10.008 ↗
8. Ferber S. · Adv. Mater. · 2019 · 190 · 38
9. 10.1016/j.vaccine.2013.04.02710.1016/j.vaccine.2013.04.027 ↗
10. 10.1016/j.biomaterials.2017.07.00110.1016/j.biomaterials.2017.07.001 ↗
11. 10.1586/erv.12.3510.1586/erv.12.35 ↗
12. 10.1016/j.coi.2012.03.00810.1016/j.coi.2012.03.008 ↗
13. 10.1016/j.molimm.2017.11.00110.1016/j.molimm.2017.11.001 ↗
14. 10.1016/j.jconrel.2019.04.02510.1016/j.jconrel.2019.04.025 ↗
15. 10.1016/j.jconrel.2015.12.00610.1016/j.jconrel.2015.12.006 ↗
16. 10.4049/jimmunol.170046710.4049/jimmunol.1700467 ↗
17. 10.1016/j.vaccine.2020.02.03410.1016/j.vaccine.2020.02.034 ↗
18. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
19. 10.1038/s41598-018-33933-710.1038/s41598-018-33933-7 ↗
20. 10.1038/ncomms1319310.1038/ncomms13193 ↗
21. 10.1038/s41551-016-001110.1038/s41551-016-0011 ↗
22. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
23. 10.1002/smll.20160006110.1002/smll.201600061 ↗
24. 10.1021/acsnano.7b0904110.1021/acsnano.7b09041 ↗
25. 10.1016/j.coi.2013.03.00110.1016/j.coi.2013.03.001 ↗
26. 10.1021/acsnano.8b0961310.1021/acsnano.8b09613 ↗
27. Bauleth-Ramos T. · Adv. Funct. Mater. · 2019 · 29 · 190368610.1002/adfm.201903686 ↗
28. 10.1002/adma.20170374010.1002/adma.201703740 ↗
29. 10.1186/s12967-017-1219-310.1186/s12967-017-1219-3 ↗
30. 10.1038/4438510.1038/44385 ↗
31. 10.1016/j.ijpharm.2011.02.00110.1016/j.ijpharm.2011.02.001 ↗
32. 10.1016/j.immuni.2018.09.02410.1016/j.immuni.2018.09.024 ↗
33. 10.1101/cshperspect.a02847210.1101/cshperspect.a028472 ↗
34. 10.1016/j.jconrel.2017.03.02810.1016/j.jconrel.2017.03.028 ↗
35. 10.1021/acsnano.7b0178610.1021/acsnano.7b01786 ↗
36. 10.1016/j.cell.2006.02.01910.1016/j.cell.2006.02.019 ↗
37. 10.1097/ppo.0b013e318234632010.1097/ppo.0b013e3182346320 ↗
38. 10.1038/nri254510.1038/nri2545 ↗
39. 10.1126/scitranslmed.aan422010.1126/scitranslmed.aan4220 ↗
40. 10.1038/cr.2009.13810.1038/cr.2009.138 ↗
41. 10.1073/pnas.050372610210.1073/pnas.0503726102 ↗
42. 10.1016/j.immuni.2012.09.02010.1016/j.immuni.2012.09.020 ↗